The transmission and control of XDR TB in South Africa: An operations research and mathematical modelling approach

Epidemiology and Infection

Volumn 136, Issue 12, 2008, Pages 1585-1598

  Basu, Sanjay ^a   Galvani, A P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Infection control; Mathematical modeling; Quarantine; South Africa; Tuberculosis extensively drug resistant

Indexed keywords

AIRBORNE INFECTION; BACTERIAL TRANSMISSION; COMMUNITY CARE; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEDICAL RESEARCH; POVERTY; PREVALENCE; RESOURCE ALLOCATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOUTH AFRICA; TUBERCULOSIS;

EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MODELS, THEORETICAL; RURAL HEALTH; SOUTH AFRICA;

EID: 55349134348     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268808000964     Document Type: Review

References (96)

1. Harvard Medical School, Open Society Institute. The Global Impact of Multi-Drug Resistant Tuberculosis. Boston: Program in Infectious Disease and Social Change, 1999.
2. South Africa Department of Health. The KZN 'outbreak'. Pretoria: DoH (http://www.doh.gov.za/docs/reports/2006/kzn/xdr.pdf, 2006). Accessed 7 May 2008.
3. Moodley P, et al. Multi- and extensively drug resistant Mycobacterium tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease 2007; 11: S56.
4. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World. Geneva: WHO, 2008.
5. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva: WHO, 2006.
6. Farmer P, et al. The dilemma of MDR-TB in the global era. International Journal of Tuberculosis and Lung Disease 1998; 2: 869-876.
7. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Medicine 2007; 4 e120.
8. Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proceedings of Biological Sciences 2001; 268: 45-52.
9. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Diseases 2003; 3: 13-21.
10. Gagneux S, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathogens 2006; 2: E61.
11. Gagneux S, et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
12. Dye C, et al. Erasing the world's slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
13. Sherman DR, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272: 1641-1643.
14. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Medicine 2004; 10: 1117-1121.
15. Shah NS, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infectious Diseases 2007; 13 (http://www.cdc.gov/EID/content/13/13/380.htm).
16. CDC. Notice to readers: Revised definition of extensively drug-resistant tuberculosis. Morbidity and Mortality Weekly Report 2006; 55: 11176.
17. Gandhi N, et al. High prevalence and mortality from extensively-drug resistant XDR. TB in TB/HIV coinfected patients in rural South Africa. THLB0210. In: XVI International AIDS Conference Toronto, 2006.
18. Gandhi NR, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
19. Health Systems Trust. Incidence of TB All Types per 100000. Durban: HST, 2007.
20. Health Systems Trust. Interruption Defaulter Rate among New Smear Positive Cases. Durban: HST, 2007.
21. Weyer K, et al. National survey of tuberculosis drug resistance in South Africa, 2001-2002. Pretoria: MRC (http://www.sahealthinfo.org/tb/natsurvey.pdf, 2003). Accessed 7 May 2008.
22. Basu S, Galvani AP. Extensively drug-resistant tuberculosis in South Africa. Lancet 2007; 369: 272-273.
23. Basu S. XDR tuberculosis requires emphasis on primary transmission. Lancet Infectious Diseases 2007; 7: 442.
24. Andrews J, et al. Clinical predictors of multidrug and extensively drug-resistant tuberculosis - Tugela Ferry, South Africa. International Journal of Tuberculosis and Lung Disease 2007; 11 S263.
25. Gandhi N. Exogenous re-infection with multi-drug and extensively drug-resistant TB among TB/HIV co-infected patients in rural South Africa. In: Fifteenth Conference on Retroviruses and Opportunistic Infections, 2008.
26. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. New England Journal of Medicine 1999; 340: 367-373.
27. Health Systems Trust. HIV Prevalence. Durban: HST, 2007.
28. WHO. Progress on Global Access to HIV Antiretroviral Therapy: A Report on '3 by 5' and Beyond. Geneva: World Health Organization, 2006.
29. Wells CD, et al. HIV infection and multidrug-resistant tuberculosis: The perfect storm. Journal of Infectious Diseases 2007; 196 (Suppl. 1): S86-107.
30. Narvskaya O, et al. Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia. European Journal of Clinical Microbiology and Infectious Diseases 2002; 21 596-602.
31. Sacks LV, et al. A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clinical Infectious Diseases 1999; 29: 96-101.
32. Moro ML, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. Aids 1998; 12: 1095-1102.
33. Nolan CM. Nosocomial multidrug-resistant tuberculosis - global spread of the third epidemic. Journal of Infectious Diseases 1997; 176: 748-751.
34. Ritacco V, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. Journal of Infectious Diseases 1997; 176: 637-642.
35. Kenyon TA, et al. A nosocomial outbreak of multidrug-resistant tuberculosis. Annals of Internal Medicine 1997; 127: 32-36.
36. Moss AR, et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. International Journal of Tuberculosis and Lung Disease 1997; 1: 115-121.
37. CDC. Multidrug-resistant tuberculosis outbreak on an HIV ward - Madrid, Spain, 1991-1995. Morbidity and Mortality Weekly Report 1996; 45: 330-333.
38. Edlin BR, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1992; 326: 1514-1521.
39. Beck-Sague C, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. Journal of the American Medical Association 1992; 268: 1280-1286.
40. Di Perri G, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989; 2: 1502-1504.
41. Coronado VG, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: Epidemiologic and restriction fragment length polymorphism analysis. Journal of Infectious Diseases 1993; 168: 1052-1055.
42. Fischl MA, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Annals of Internal Medicine 1992; 117: 177-183.
43. Shah S. Personal communication to S. Basu, 4 March 2008.
44. South African Press Association. XDR-TB found in all provinces. Durban: SAPA, 12 February 2007.
45. Pillay V, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clinical Infectious Diseases 2007; 45: 1409-1414.
46. Sturm AW. Multi- and extensively drug resistant tuberculosis in South Africa. Durban: Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 2007.
47. Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: No time for denial or complacency. PLoS Medicine 2007; 4: E50.
48. Associated Press. Patients with drug-resistant TB escape, 18 December 2007.
49. Dugger CW. TB Patients chafe under lockdown in South Africa. New York Times, 2008.
50. Nardell E. Transmission and safety issues. In: Friedman LN, ed. Tuberculosis: Current Concepts and Treatment. New York: Informa Healthcare, 2000, pp. 50-71.
51. South Africa Department of Health. Tuberculosis Strategic Plan for South Africa, 2007-2011. Pretoria: DOH, 2007.
52. Bock NN, et al. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. Journal of Infectious Diseases 2007; 196 (Suppl. 1): S108-113.
53. Corbett EL, et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Medicine 2007; 4: E22.
54. Open Society Institute, Medecins sans Frontieres, Treatment Action Campaign. Time for change: New approaches for managing drug-resistant TB in regions with high HIV rates. In: Union World Conference on Lung Health, Cape Town, 2007.
55. Behr MA. Tuberculosis due to multiple strains: A concern for the patient? A concern for tuberculosis control? American Journal of Respiratory and Critical Care Medicine 2004; 169: 554-555.
56. Lopez B, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clinical and Experimental Immunology 2003; 133: 30-37.
57. Manabe YC, et al. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infection and Immunity 2003; 71: 6004-6011.
58. Manca C, et al. Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infection and Immunity 2004; 72: 5511-5514.
59. Manca C., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/ beta. Proceedings of the National Academy of Sciences USA 2001; 98: 5752-5757.
60. Special Programme for Tropical Diseases Research. Diagnostics for Tuberculosis: Global Demand and Market Potential. Geneva: WHO, 2006.
61. Espinal MA, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries. Journal of the American Medical Association 2000; 283: 2537-2545.
62. Espinal M. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. International Journal of Tuberculosis and Lung Disease 2003; 7: 607-608.
63. Moll A, et al. Extensively drug-resistant XDR. TB more common than MDR TB in Tugela Ferry, South Africa with evidence for resistance amplification over time. International Journal of Tuberculosis and Lung Disease 2007; 11: S240-241.
64. Mitnick C, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of Medicine 2003; 348: 119-128.
65. Basu S, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: An epidemiological modelling study. Lancet 2007; 370 1500-1507.
66. Iseman MD. A Clinician's Guide to Tuberculosis. Hagerstown: Lippincott Williams & Wilkins, 2000.
67. Wells WF. Airborne Contagion and Air Hygiene: An Ecological Study of Droplet Infections. Cambridge: Harvard University Press, 1955.
68. Riley EC, Murphy G, Riley RL. Airborne spread of measles in a suburban elementary school. American Journal of Epidemiology 1978; 107: 421-432.
69. Escombe AR, et al. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clinical Infectious Diseases 2007; 44: 1349-1357.
70. Riley RL, et al. Infectiousness of air from a tuberculosis ward. American Review of Respiratory Disease 1962; 85: 511-525.
71. Nardell EA, et al. Airborne infection. Theoretical limits of protection achievable by building ventilation. American Review of Respiratory Disease 1991; 144: 302-306.
72. Riley RL, Nardell EA. Clearing the air. The theory and application of ultraviolet air disinfection. American Review of Respiratory Disease 1989; 139: 1286-1294.
73. Kawai V, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. American Journal of Tropical Medicine and Hygiene 2006; 75: 1027-1033.
74. Gammaitoni L, Nucci MC. Using a mathematical model to evaluate the efficacy of TB control measures. Emerging Infectious Diseases 1997; 3: 335-342.
75. Noakes CJ, et al. Modelling the transmission of airborne infections in enclosed spaces. Epidemiology and Infection 2006; 134: 1082-1091.
76. Kleinrock L. Queueing Systems, Theory. New York: Wiley, 1975.
77. Jensen PA, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. Morbidity and Mortality Weekly Report 2005; 54: 1-141.
78. Escombe AR, et al. Natural ventilation for the prevention of airborne contagion. PLoS Medicine 2007; 4: E68.
79. Lee K, Slavcev A, Nicas M. Respiratory protection against Mycobacterium tuberculosis: Quantitative fit test outcomes for five type N95 filtering-facepiece respirators. Journal of Occupational and Environmental Hygiene 2004; 1: 22-28.
80. Tokars JI, et al. Use and efficacy of tuberculosis infection control practices at hospitals with previous outbreaks of multidrug-resistant tuberculosis. Infection Control and Hospital Epidemiology 2001; 22: 449-455.
81. Moro ML, et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. International Journal of Tuberculosis and Lung Disease 2000; 4: 61-68.
82. Rich ML. The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. Boston: Harvard University, 2003.
83. Posel D, Casal D. What has been happening to internal labour migration in South Africa. In: Conference on Labour Markets and Poverty in South Africa. Pretoria, 2002.
84. Crush J, et al. Migration and HIV/AIDS in South Africa. Development Southern Africa 2005; 22: 293-317.
85. Williams B, et al. Occupational health, occupational illness: Tuberculosis, silicosis and HIV on South African Mines. In: Banks DE, Parker JE, eds. Occupational Lung Disease: An International Perspective. London: Chapman and Hall, 1998.
86. Anglogold Ashanti. Case studies: South Africa. Johannesburg, 2006.
87. Gupta R, et al. Public health. Responding to market failures in tuberculosis control. Science 2001; 293: 1049-1051.
88. Moore DA, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. New England Journal of Medicine 2006; 355: 1539-1550.
89. Vella V, et al. Surveillance of XDR and MDR at COSH, 2005-2006. Tugela Ferry: KwaZulu Natal Department of Health, 2007.
90. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press, 1991.
91. Blower SM, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nature Medicine 1995; 1: 815-821.
92. Dye C, et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352: 1886-1891.
93. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proceedings of the National Academy of Sciences USA 2000; 97: 8180-8185.
94. Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: The case for mass vaccination. Proceedings of the National Academy of Sciences USA 2002; 99: 10935-10940.
95. UNFPA. The Day of 6 Billion. Geneva: United Nations, 1999.
96. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-1537.